Condition (MeSH)
Histiocytosis, Sinus
ClinicalTrials.gov lists 9 trials for Histiocytosis, Sinus or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Histiocytosis, Sinus itself; the rest are tagged with a narrower condition beneath it.
When did Histiocytosis, Sinus trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 4
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 3 |
| 2017 | 1 |
| 2014 | 1 |
| 2011 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Histiocytosis, Sinus trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 4 | 1 |
| Observational | 3 |
How many Histiocytosis, Sinus trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 7 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Histiocytosis, Sinus? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. | Molecular cancer therapeutics | 2019 | Yes |
| Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. | Blood | 2018 | Yes |
| Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. | Blood | 2014 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Rosaï-Dorfman disease | Cases families | Worldwide | Not stated | Exact | |
| Rosaï-Dorfman disease | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Rosaï-Dorfman disease | Cases families | Worldwide | Not stated | Exact | |
| Rosaï-Dorfman disease | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Rosaï-Dorfman disease | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Rosaï-Dorfman disease | 158014 | Exact | Orphadata Science knowledge files, Product 1 |
| Rosaï-Dorfman disease | 158014 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.